1. Introduction {#sec1}
===============

Acute aortic dissection (AAD) is one of the most serious acute aorta syndrome characterized by severe chest and/or back pain. AAD of the ascending aorta is highly lethal (a mortality rate of 1%-2% per hour early after symptom onset) that requires prompt diagnosis and surgical intervention to optimize outcomes \[[@B1]--[@B3]\]. The etiologies include not only mechanical stimulation such as hypertension and trauma but also vascular injury caused by atherosclerosis, inflammation, and connective tissue disease \[[@B4]\]. Despite recent progress in recognition of the diagnostic and therapeutic advances, clinicians are far from comfortable in defining an optimal therapy to manage aortic dissection, and AAD is still a focus and key point in the field of cardiovascular surgery and critical care so far.

AAD is a surgical emergency occurring when an intima of the aorta is damaged and ruptured and blood enters the media creating a false lumen between the two layers. The typical pathophysiological changes include large modifications to the extracellular matrix, oxidative stress, inflammatory response, vascular smooth muscle (VSM) hypertrophy, and high expression of metalloproteinase, which directly lead to the compensatory hyperplasia of collagen fiber, apoptosis and phenotypic transformation of vascular smooth muscle cells (VSMCs), and steady degradation of the extracellular matrix proteins in the aortic wall \[[@B5]--[@B13]\]. Current research showed that the activation of the TGF-*β*1 signaling pathway and high expression of its downstream matrix metalloproteinase (MMPs) are involved in the pathogenesis of AAD \[[@B14]--[@B16]\]. Studies also have found that the PI3K/AKT signaling pathway contributes to phenotypic switching of vascular smooth muscle cell (VSMC) and induces apoptosis \[[@B17]--[@B19]\]. However, detailed molecular mechanisms still need to be explored.

Quantitative mass spectrometry (MS) is an adjunctive tool to help understand the mechanisms of many diseases \[[@B20]\]. Large-scale identification of differential abundance proteins (DAPs) can be used to identify key proteins, and immunohistochemistry is an important traditional technique used to verify the selected proteins. The objective of this study was to identify and quantify DAPs of aortic arch tissues in patients with AAD using TMT-labelled MS and further to verify the selected DAPs of interest using immunohistochemistry, by which we hope to find some possible proteins involved in the pathogenesis of AAD. A flowchart to illustrate this study is shown in [Figure 1](#fig1){ref-type="fig"}.

2. Materials and Methods {#sec2}
========================

2.1. Tandem Mass Tag Labelling {#sec2.1}
------------------------------

### 2.1.1. Sample {#sec2.1.1}

The dissected aortic tissues (aortic arch including all layers of the wall: intima, media, and adventitia) from 5 AAD patients were extracted during surgery. In addition, one piece of healthy aortic arch tissue was obtained from a 44-year-old male donor. CTA was performed in all patients to confirm the diagnosis (all were Stanford type A dissection). Four out of them with hypertension history complained of chest and/or back pain, while one 22-year-old patient, with no history of hypertension and trauma, no family history of Marfan syndrome, and no typical clinical symptoms, was diagnosed with AAD. The clinical features and more detailed description of dissected aortic samples are summarized in Supplementary Table [1](#supplementary-material-1){ref-type="supplementary-material"}.

All tissues were collected as typical lesion specimens of approximately 1.0 × 1.0 cm^2^ in size. Specimens were immediately placed in an ice-bath, RNA-free specimen box and transferred to a −80°C refrigerator for preservation. The study was approved by the ethics committee of Zhongshan Hospital, Fudan University (Shanghai, China). Informed consent was obtained from patients or their legal surrogates before enrolment.

### 2.1.2. Sample Pretreatment {#sec2.1.2}

Tissues were carefully pulled out from the frozen tubes, cut into pieces, weighed about 50 mg, added 10 times extraction buffer, and extracted protein with a grinding mill. The extracted samples were spun to remove the residue of tissues. The protein concentration of the extracted sample solution was measured with a BCA Protein Assay kit (Pierce). Proteins extracted from tissue were precipitated with a TCA Protein Precipitation Kit (QYBIO). The protein pellet was dried out by SpeedVac. The pellet was subsequently dissolved with 8 M urea in 100 mM Tris-Cl (pH 8.5, Sigma). Tris(2-carboxyethyl)phosphine (TCEP, final concentration is 5 mM, Thermo Scientific) and iodoacetamide (final concentration is 10 mM, Sigma) were added to the solution and incubated at room temperature for 20 and 15 minutes for reduction and alkylation, respectively. The solution was digested with LysC at 1 : 100 (*w*/*w*) (Promega) for 4 h and then diluted four times and digested with trypsin at 1 : 50 (*w*/*w*) (Promega) for 16 h. The digested peptide mixtures were labelled with the TMT kit (6-plex, Thermo).

### 2.1.3. Liquid Chromatography Tandem Mass Spectrometry Analysis of Peptides {#sec2.1.3}

For multidimensional protein identification technology (MudPIT), total peptide mixtures were pressure loaded onto a biphasic-fused silica capillary column. The entire column setting (biphasic column-union-analytical column) was placed in line with an Agilent 1200 quaternary high-performance liquid chromatography pump (Palo Alto, CA) for MS analysis. The digested proteins were analyzed using a 12-step MudPIT separation method \[[@B21]\] as described previously.

### 2.1.4. Mass Spectrometry Condition {#sec2.1.4}

Data-dependent tandem mass spectrometry (MS/MS) analysis was performed with an Orbitrap mass spectrometer (Thermo Scientific, San Jose, CA). Peptides eluted from the liquid chromatography system were directly electrosprayed into the mass spectrometer with a distal 1.5 kV spray voltage. One acquisition cycle included one full-scan MS spectrum (*m*/*z*, 300--1800), followed by the top 20 MS/MS events.

### 2.1.5. Data Analysis {#sec2.1.5}

The acquired MS/MS data were analyzed against a Uniprot Homo sapiens database (database released on Sep. 24, 2015) using Integrated Proteomics Pipeline (IP2, <http://integratedproteomics.com/>). To estimate peptide probabilities and false discovery rates accurately, we used a decoy database containing the reversed sequences of all the proteins appended to the target database. Carbamidomethylation of cysteine was considered as a static modification.

2.2. Immunohistochemistry {#sec2.2}
-------------------------

### 2.2.1. Sample {#sec2.2.1}

The aortic arch tissue\'s paraffin sections of another 20 patients with AAD and 10 healthy donors were performed and provided by the Pathological Sample Library of Zhongshan Hospital of Fudan University. The standardized method to fix the tissues would be operated by professional staff as follows: approximately 1.0 × 1.0 × 0.2 cm^3^ of tissue would be extracted during surgery and fixed with formalin rapidly for 24 h; paraffin sections are performed and stored in the sample library. The basic clinical information is shown in Supplementary Table [3](#supplementary-material-1){ref-type="supplementary-material"}. The study was also approved by the ethics committee of Zhongshan Hospital of Fudan University.

### 2.2.2. Immunohistochemistry Method {#sec2.2.2}

The expression of integrin alpha 3 (ITGA-3) and integrin alpha 5 (ITGA-5) were compared stained with DAB staining and hematoxylin. Briefly, paraffin sections were dewaxed, and antigen was retrieved by citric acid buffer. The primary antibody of ITGA-3 and ITGA-5 is the rabbit antibody (Abcam, ab131055 and ab239400, respectively, 1 : 100). The corresponding secondary antibody is HRP-goat anti-rabbit IgG (H+L) (GXYbio, S8002, 1 : 100). The sections were reacted with the DAB kit (ZSGB-BIO, China, ZLI-9019). Eight separate views (magnification = original × 400) were randomly selected. The integrated option density (IOD) of ITGA-3 and ITGA-5 was chosen to determine the protein semiquantitative expression. Free ImageJ software (version 1.2; WS Rasband, National Institute of Health, Bethesda, MD) was used to conduct deconvolution and downstream analysis \[[@B22]\], and then, the Mann-Whitney test of the IOD was performed using SPSS software (version 25.0, IBM).

3. Results {#sec3}
==========

3.1. Identification Differential Abundance Proteins (DAPs) of Ascending Aorta Tissues in Patients with AAD Using TMT Quantitative Proteomics {#sec3.1}
--------------------------------------------------------------------------------------------------------------------------------------------

TMT-labelled MS analysis was performed on fresh aortic arch tissues of 5 AAD patients and one healthy donor. Principal component analysis (PCA) clustergram was created using OmicsBean software from proteins identified by quantitative MS. Except patient 1, other patients have consistent clustering as shown in PCA and heat map analysis ([Figure 2](#fig2){ref-type="fig"}). Patient 1 might fall in different subtypes of AAD compared with the other patients.

A total of 809 proteins were identified from individual unique peptides (Supplementary Table [2](#supplementary-material-1){ref-type="supplementary-material"}). Limited by the number of the healthy control, we defined the identified proteins as DAPs if there was a log~2~FC in excess of 2 or in less of -2.132 proteins changed significantly (32 upregulated and 100 downregulated) in AAD patients compared with the healthy donor (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}).

To explain the cellular localization and associated functions of DAPs, gene Ontology analysis (GO analysis) was performed by Blast2GO software (version 4) to provide further understanding of these results by biological processes, cell components, and molecular function ([Figure 3](#fig3){ref-type="fig"}). According to the GO results, most DAPs were located in the extracellular region part and participated in several functions, such as cell junction, metabolic process, and developmental process, indicating that proteins involved in extracellular activities were important in AAD tissues. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was used to classify the functional annotations of DAPs. Interestingly, among the 30 significantly enriched pathways, most of downregulated DAPs (*n* = 16/51) were found in the PI3K-AKT signaling pathway ([Figure 4](#fig4){ref-type="fig"}). Protein-protein interaction (PPI) analysis further suggested that ITGA-3 and ITGA-5 were important nodes in the PI3K-AKT signaling pathway ([Figure 5](#fig5){ref-type="fig"}).

3.2. Verification of the Levels of ITGA-3 and ITGA-5 by Immunohistochemistry {#sec3.2}
----------------------------------------------------------------------------

The levels of ITGA-3 and ITGA-5 in pathological sections of 20 AAD patients and 10 healthy donors were further assessed by immunohistochemistry ([Figure 6(a)](#fig6){ref-type="fig"}). The basic information of them is shown in Supplementary Table [3](#supplementary-material-1){ref-type="supplementary-material"}. The IOD of ITGA-3 and ITGA-5 in AAD patients was significantly lower compared with healthy donors (*P* \< 0.001) ([Figure 6(b)](#fig6){ref-type="fig"}).

4. Discussion {#sec4}
=============

AAD of the ascending aorta is a life-threatening cardiovascular emergency with a mortality rate of 1% to 2% per hour early after the symptom onset \[[@B1], [@B3]\]. With increasing incidence of hypertension, the morbidity of AAD has increased annually in recent years \[[@B23]\]. However, the detailed molecular mechanisms of this disease have yet to be clarified. Finding out important proteins in dissected aorta tissues of patients with AAD can help to elucidate the pathogenesis of this disease.

In this study, the quantitative proteomics showed that 100 proteins were significantly downregulated while 32 upregulated in dissected aorta tissues of AAD patients compared with those in ascending aorta tissue of the healthy donor. Bioinformatic analysis revealed that most DAPs were primarily located in the extracellular region part and their biological functions mainly focused on cell junction, metabolic process, and developmental process. Interestingly, the PI3K-AKT signaling pathway was selected by KEGG analysis, which has been reported involved in a series of biological processes by transducing stimulatory extracellular signals to the nucleus, including proliferation, apoptosis, angiogenesis, and tumor growth \[[@B24], [@B25]\]. Liu and his colleagues demonstrated that the PI3K/AKT signaling transduction pathway was involved in rat vascular smooth muscle cell proliferation induced by apelin-13 \[[@B18]\]. Other studies also have shown that the 0PI3K/AKT signaling pathway contributes to VSMC dysfunction, vasoconstriction, and vascular remodeling \[[@B19], [@B26]\]. However, few studies reported the molecule or protein in the PI3K/AKT signaling pathway contributing to the VSMC dysfunction in human aorta tissues.

In this study, we found that integrins, especially ITGA-3 and ITGA-5, were significantly downregulated in dissected aorta tissues of AAD patients. As expected, ITGA-3 and ITGA-5 showed a strong downexpression in the cytomembrane and cytoplasm. As a kind of cell surface adhesion molecule with signal transduction function, integrins are key transmembrane protein upstream in the P13K-AKT signaling pathway. By connecting the extracellular matrix with actin cytoskeleton, it can maintain cell morphology and mediate cell adhesion, proliferation, differentiation, and other physiological processes according to the types of extracellular ligands. Downregulation of integrin may affect the stability of cytoskeleton, thus ultimately affecting the physiological function of cells \[[@B27], [@B28]\]. Taken together, downregulation of ITGA-3 and ITGA-5 might be involved in the pathogenesis of AAD by reducing the adhesion between cell and extracellular matrix and modulating the focal adhesion pathway.

The proteomic approach provides an exciting platform for determining the pathogenesis of aortic dissection. As an initial step, our study identified the downregulation of ITGA-3 and ITGA-5, both of which may participate in AAD pathogenesis via the focal adhesion pathway. To make up for the control sample shortage in the proteomic study, we obtained the pathological sections of another 10 healthy donors and 20 AAD patients from the Pathological Sample Library of Zhongshan Hospital to further make our results credible in the following validation test. The performance of the PI3K-AKT signaling pathway needs to activate downstream proteins, which provides insights into the specific molecule or signaling pathway contributing to the pathogenesis of aortic dissection. It needs to be further explored in animals and humans.

5. Conclusions {#sec5}
==============

The aortic arch tissues of patients with AAD show a large number of DAPs, the molecular functions of which were primarily cell junction. In particular, ITGA-3 and ITGA-5 were highly differentially expressed in these tissues. Downregulation of the two proteins may contribute to the progression of AAD, which may serve as a diagnostic biomarker and a novel therapeutic target in AAD.
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###### 

Supplementary Table 1 Basic data between AAD patients and healthy control in the TMT method. Note: ^a^"0" is no; "1" is yes. ^b^According to the more popular Stanford system, dissections involving the ascending aorta are classified as type A, whereas those involving only the descending aorta are classified as type B.

###### 

Click here for additional data file.

###### 

Supplementary Table 2 List of expreesion of all identified proteins between the two groups in the TMT method.

###### 

Click here for additional data file.

###### 

Supplementary Table 3 Basic data between AAD patients and healthy controls in immunohistochemistry. Note: ^a^"0" is no; "1" is yes. ^b^According to the more popular Stanford system, dissections involving the ascending aorta are classified as type A, whereas those involving only the descending aorta are classified as type B.

###### 

Click here for additional data file.

![Experimental flowchart. The aortic arch tissues of 5 patients with AAD were extracted during surgery. The peptides labelled with TMT were prepared, and a MS/MS analysis was performed. The proteomic data were analyzed, and the DAPs were selected and verified by immunohistochemistry.](BMRI2020-1068402.001){#fig1}

![Principal component analysis (PCA) and heat map of proteome data. (a) Principal component analysis of the proteome data in a 2D graph of PC1 and PC2. (b) Expression heat map of the proteome data in the samples.](BMRI2020-1068402.002){#fig2}

![The Gene Ontology (GO) enrichment of 132 differential abundance proteins (DAPs). (a) Sorted by descending order of the number of protein associated with the listed GO ID. (b) Sorted by descending order of *P* value for the GO enrichment terms. Because of the limited number of patients, we considered DAPs as meaningful only as strong differently expressed (∣log~2~FC \| \>2).](BMRI2020-1068402.003){#fig3}

![Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for 132 DAPs between health donor vs. patients. (a) Top 30 significantly enriched pathways were shown in the senior bubble chart. The rich factor is the ratio of DAP numbers annotated in this pathway term to all gene numbers annotated in this pathway term (*P* \< 0.01). (b) Most of downregulated DAPs (*n* = 16/51) were found in the PI3K-AKT signaling pathway.](BMRI2020-1068402.004){#fig4}

![The protein-protein interaction networks is analyzed by string software. Different line colours represent the types of evidence used in predicting the associations: gene fusion (red), neighborhood (green), cooccurrence across genomes (blue), coexpression (black), experimental (purple), association in curated databases (light blue), or comentioned in PubMed abstracts (yellow).](BMRI2020-1068402.005){#fig5}

![The biomarkers (ITGA-3, ITGA-5) verified by immunohistochemistry (IHC). (a) The black arrows present positive signals of ITGA-3 and ITGA-5 staining by DAB in healthy donors. Negative control: the section was stained with secondary antibodies only. Scale bars = 200 *μ*m. (b) The IODs of ITGA-3 and ITGA-5 in AAD patients were significantly lower compared with healthy donors (^∗∗∗^*P* \< 0.001).](BMRI2020-1068402.006){#fig6}

###### 

Upregulated differential abundance proteins in AAD patients (*n* = 32).

  Accession    Expression of healthy donor   Mean expression of AAD patients (*n* = 5)   log~2~FC   Description
  ------------ ----------------------------- ------------------------------------------- ---------- ----------------------------------------------------------------------------------------------
  Q14315       324.67                        7870.896                                    4.599      Filamin-C
  Q5U0D2       204                           3628.784                                    4.153      Transgelin
  P37802       2044.82                       28287.816                                   3.79       Transgelin-2
  B0AZV6       471.5                         5283.69                                     3.486      cDNA, FLJ79546, highly similar to SH3 domain-binding glutamic acid-rich-like protein
  J3KND3       180                           1960.68                                     3.445      Myosin light polypeptide 6
  A8KAH9       565                           6078.1                                      3.427      RAP1A, member of RAS oncogene family
  A0A024QZQ2   267                           2674.5                                      3.324      Prosaposin (Variant Gaucher disease and variant metachromatic leukodystrophy), isoform CRA_b
  A0A024RAB6   368.77                        3658.2                                      3.31       Heparan sulfate proteoglycan 2 (Perlecan), isoform CRA_b
  P08294       718                           6862.38                                     3.257      Extracellular superoxide dismutase \[Cu-Zn\]
  F2RM37       315.5                         2933.168                                    3.217      Coagulation factor IX
  A0A024R321   236.44                        2162.786                                    3.193      Filamin-B, beta (actin binding protein 278), isoform CRA_a
  B4DHX4       241.5                         2181.672                                    3.175      cDNA FLJ52902, highly similar to Rab GDP dissociation inhibitor alpha
  A6NIZ1       565                           5073.772                                    3.167      Ras-related protein Rap-1b-like protein
  A0A024QZX3   180                           1546.584                                    3.103      Serpin peptidase inhibitor, clade B (Ovalbumin), member 6, isoform CRA_a
  Q53HQ0       270                           2227.7                                      3.045      Flotillin 1 variant (fragment)
  A6NLG9       252.8                         2077.26                                     3.039      cDNA FLJ36740 fis, clone UTERU2013322, highly similar to Biglycan
  A5YM53       229                           1812.1875                                   2.984      ITGAV protein
  V9HWF6       287.5                         2256.258                                    2.972      Alpha 1-acid glycoprotein
  B2RDY9       190                           1426.9175                                   2.909      Adenylyl cyclase-associated protein
  B4DLV7       311.17                        2185.602                                    2.812      cDNA FLJ60299, highly similar to Rab GDP dissociation inhibitor beta
  P01031       461                           3067.166667                                 2.734      Complement C5
  Q9NZM1       201                           1334.328                                    2.731      Myoferlin
  P13645       870.5                         5446.79                                     2.645      Keratin, type I cytoskeletal 10
  P08779       1462.67                       8870.308                                    2.6        Keratin, type I cytoskeletal 16
  B1N7B8       201                           1028.0625                                   2.355      Cryocrystalglobulin CC1 kappa light chain variable region (fragment)
  A0A024RBX9   256                           1281.3                                      2.323      Pyruvate dehydrogenase E1 component subunit alpha
  Q7Z7J6       241.25                        1205.772                                    2.321      Actin alpha 1 skeletal muscle protein
  B7Z6P1       266.05                        1306.056                                    2.295      cDNA FLJ53662, highly similar to actin, alpha skeletal muscle
  A8K4W0       347                           1656.5                                      2.255      40S ribosomal protein S3a
  A0A024R821   451                           1989.75                                     2.141      Eukaryotic translation initiation factor 3 subunit B
  P07357       947                           4078                                        2.106      Complement component C8 alpha chain
  G3V4G1       274                           1140                                        2.057      Neuroguidin (fragment)

Note: based on protein abundance. A protein was defined as DAPs if there was a log2FC in excess of 2. FC: fold change.

###### 

Downregulated DAPs in AAD patients (*n* = 100).

  Accession    Expression of healthy donor   Mean expression of AAD patients (*n* = 5)   log~2~FC      Description
  ------------ ----------------------------- ------------------------------------------- ------------- -----------------------------------------------------------------------------------------------------------------------
  H3BQZ7       2286.5                        69.33333333                                 -5.04344799   HCG2044799
  Q6GMX6       24204.11                      1024.248                                    -4.56261507   IGH@ protein
  Q6MZQ6       21830.2                       939.36                                      -4.53850338   Putative uncharacterized protein DKFZp686G11190
  Q6N089       19877.09                      909.564                                     -4.4497876    Putative uncharacterized protein DKFZp686P15220
  V9HW68       19889.09                      1004.376                                    -4.3076059    Epididymis luminal protein 214
  Q92626       2750                          187.25                                      -3.87639399   Peroxidasin homolog
  A0A024R971   5098                          368.058                                     -3.79192634   Fibromodulin, isoform CRA_a
  A0A087X2C0   5633                          410.31                                      -3.77911725   Ig mu chain C region
  A0A024R9G4   1679                          122.6666667                                 -3.77478706   Family with sequence similarity 49, member B, isoform CRA_a
  A0A0G2JPD4   6460.29                       505.912                                     -3.67464056   Uncharacterized protein
  B0YJ88       4307                          350.696                                     -3.61839044   Radixin
  Q96C32       9160.43                       752.5633333                                 -3.60553042   Polyubiquitin-C
  A8K3Q7       19376                         1632.302                                    -3.56929086   Annexin
  P43652       2496.5                        211.875                                     -3.55862163   Afamin
  A0A024R0S6   5116.29                       460.624                                     -3.47343655   EH-domain containing 2, isoform CRA_a
  Q9NZU5       5750                          529.346                                     -3.44127902   LIM and cysteine-rich domains protein 1
  F2ZC06       3779.75                       349.452                                     -3.43512461   Thyroid hormone receptor interacting protein 6 isoform 1
  P26006       4296                          414.25                                      -3.37442039   Integrin alpha 3/beta 1
  A8MX94       5754.4                        581.104                                     -3.30779722   Glutathione S-transferase P
  B2R6V9       1398                          142                                         -3.29940153   cDNA, FLJ93141, highly similar to Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1), mRNA
  P01023       3824.29                       397.764                                     -3.26520731   Alpha 2-macroglobulin
  O94832       1636                          170.944                                     -3.25857706   Unconventional myosin-Id
  B4DKT9       4013                          422.1666667                                 -3.24879658   cDNA FLJ54052, highly similar to alpha 1 catenin (cadherin-associated protein)
  D6RA82       5307.67                       564.375                                     -3.23335269   Annexin
  B4DQG5       2126.25                       227.9175                                    -3.22172763   cDNA FLJ54122, highly similar to Cytosol aminopeptidase (EC 3.4.11.1)
  P12235       1117                          125.3333333                                 -3.15578712   ADP/ATP translocase 1
  A0A024QZV0   1431                          160.625                                     -3.15525531   HCG1811539, isoform CRA_b
  Q6UVK1       1875                          210.564                                     -3.15455989   Chondroitin sulfate proteoglycan 4
  A0A0B4J1R6   1682.75                       191.546                                     -3.13505805   Transketolase
  B4DRV4       2956                          340.5                                       -3.11791957   cDNA FLJ55667, highly similar to secreted protein acidic and rich in cysteine
  A0A024RC65   4177                          531.732                                     -2.97369595   HCG1991735, isoform CRA_a
  A0A024RDE1   1252                          161.95                                      -2.95061419   SPARC-like 1 (Mast9, hevin), isoform CRA_a
  Q8TCD0       14216                         1858.354                                    -2.93541833   Uncharacterized protein
  A0A024RAC9   253                           34                                          -2.89553073   Zinc finger, UBR1 type 1, isoform CRA_c
  O76024       2314                          313                                         -2.8861543    Wolframin
  B4DQX8       3990                          547.875                                     -2.86447007   cDNA FLJ51723, highly similar to DCC-interacting protein 13 alpha (fragment)
  V9HWK1       2754                          387.9425                                    -2.82761382   Triosephosphate isomerase
  P49327       1231.5                        174.842                                     -2.81629294   Fatty acid synthase
  B4DNM8       360                           51.75                                       -2.79836614   cDNA FLJ53395, highly similar to Prolyl 3-hydroxylase 1 (EC 1.14.11.7)
  A0A087WZW8   14216                         2052.316                                    -2.7921908    Protein IGKV3-11
  A0A087WUS7   2422                          354.7                                       -2.77152763   Ig delta chain C region
  B4E3A8       1457                          216.3333333                                 -2.75167299   cDNA FLJ53963, highly similar to leukocyte elastase inhibitor
  A8K3B6       406                           60.5                                        -2.74647268   Nonspecific protein-tyrosine kinase
  S6C4R6       12602.88                      1884.586                                    -2.74143392   IgG L chain
  A0A087WYL9   14216                         2132.92                                     -2.73661383   Ig kappa chain C region
  Q6GMX0       11199.11                      1698.368                                    -2.72116309   Uncharacterized protein
  Q6PJF2       9283.64                       1452.93                                     -2.67572538   IGK@ protein
  P27824       1292.5                        204.5                                       -2.65999153   Calnexin
  Q6P5S8       14216                         2252.75                                     -2.65775646   IGK@ protein
  A0A087X130   12702.62                      2022.842                                    -2.65067055   Ig kappa chain C region
  A0A087WWT3   646                           104                                         -2.63495064   Serum albumin
  V9HW34       9283.64                       1502.036                                    -2.62777119   Epididymis luminal protein 213
  Q8NCL6       2879.25                       479.72                                      -2.58542857   cDNA FLJ90170 fis, clone MAMMA1000370, highly similar to Ig alpha 1 chain C region
  Q9NPP6       3076.09                       515.486                                     -2.57709256   Immunoglobulin heavy chain variant (fragment)
  Q96K68       2872.08                       483.564                                     -2.57031719   cDNA FLJ14473 fis, clone MAMMA1001080, highly similar to Homo sapiens SNC73 protein (SNC73) mRNA
  B4DEA3       218                           37                                          -2.55873096   cDNA FLJ56531, highly similar to UV excision repair protein RAD23 homolog B
  Q96CD0       228.5                         41                                          -2.47849835   F-box/LRR-repeat protein 8
  V9HWF2       1684.5                        306.8175                                    -2.45686775   Malate dehydrogenase
  A8K4C8       5080                          925.6666667                                 -2.45626382   60S ribosomal protein L13
  A0A024RDY2   860                           158.994                                     -2.43536434   Tumor protein, translationally controlled 1, isoform CRA_a
  Q6MZV6       2675.38                       500.17                                      -2.41925339   Putative uncharacterized protein DKFZp686L19235
  A0A024RB01   2564                          484.4                                       -2.40412549   Integrin, alpha 5 (fibronectin receptor, alpha polypeptide), isoform CRA_b
  A6NLN1       652                           123.9175                                    -2.39549202   Polypyrimidine tract binding protein 1, isoform CRA_b
  P07204       989                           190.33                                      -2.37746754   Thrombomodulin
  F6U211       253                           49.46666667                                 -2.35460879   40S ribosomal protein S10
  P63267       1432                          283.6666667                                 -2.33576296   Actin, gamma-enteric smooth muscle
  A0A0C4DFX3   829                           164.6666667                                 -2.33182356   EMILIN-1
  A6NNI4       571                           114.3333333                                 -2.32024467   Tetraspanin
  A0A024RA21   843                           170.8                                       -2.30322466   Secernin 1, isoform CRA_a
  B2R5H0       1174                          245.915                                     -2.25520077   Protein S100
  B4DPU3       7412                          1556.5                                      -2.2515573    cDNA FLJ56548, highly similar to elongation factor 2
  Q6MZU6       6876.26                       1445.532                                    -2.25002355   Putative uncharacterized protein DKFZp686C15213
  A0A024R1N1   1066                          224.5                                       -2.24742009   Myosin, heavy polypeptide 9, nonmuscle, isoform CRA_a
  A0A075B6N8   6872.24                       1450.324                                    -2.24440519   Ig gamma-3 chain C region (fragment)
  B7Z539       898                           192.05                                      -2.22523348   cDNA FLJ56954, highly similar to interalpha trypsin inhibitor heavy chain H1
  A0A024R930   232                           49.75                                       -2.22135637   Proteoglycan 4, isoform CRA_a
  A8K9M5       1651.17                       354.448                                     -2.21984277   cDNA FLJ77947, highly similar to human complement protein C8 beta subunit mRNA
  A0A024R7Z5   412.5                         89.2075                                     -2.20915721   Syndecan binding protein (Syntenin), isoform CRA_c
  B4DDS8       846                           184.5                                       -2.19703685   cDNA FLJ56686, moderately similar to FADD protein
  A0A024R3W7   239                           52.5                                        -2.18662129   Eukaryotic translation elongation factor 1 beta 2, isoform CRA_a
  A0A087WUN8   371                           82                                          -2.17772337   Syntaxin-binding protein 2
  B4DTX5       1412                          314.816                                     -2.16515932   cDNA FLJ60072, highly similar to Homo sapiens sorbin and SH3 domain containing 1 (SORBS1), transcript variant 6, mRNA
  Q9BVK6       267                           59.75                                       -2.15982912   Transmembrane emp24 domain-containing protein 9
  Q9Y217       430                           96.33333333                                 -2.15822967   Myotubularin-related protein 6
  Q8IWB1       194                           43.5                                        -2.15696935   Inositol 1,4,5-trisphosphate receptor-interacting protein
  A0A075B6G3   818.5                         183.5766667                                 -2.15659972   Dystrophin
  K7EQQ3       6367                          1439.5                                      -2.14504598   Keratin, type I cytoskeletal 9
  B4E2F9       1999.32                       455.736                                     -2.13323916   cDNA FLJ57038, highly similar to Filamin-A
  C9JAK5       1520                          346.7                                       -2.13231158   ADP-ribosylation factor 4
  B7Z9B7       1412                          322.75                                      -2.12925109   cDNA FLJ54732, moderately similar to sorbin and SH3 domain-containing protein 1
  B2ZZ89       884                           202.512                                     -2.12603897   Epididymis luminal protein 102
  A0M8W4       902                           207.5                                       -2.1200161    Ubiquitin-conjugating enzyme E2 variant 2
  B0QZ18       3015                          723.296                                     -2.05949992   Copine-1
  A0A024RAX0   676                           162.25                                      -2.05880477   Matrix Gla protein
  B0QY01       225                           54.125                                      -2.05555798   Target of Myb protein 1 (fragment)
  A0A087WU08   2574                          619.875                                     -2.05396283   Haptoglobin
  A0A024R6P0   2748                          666.416                                     -2.04388706   Serpin peptidase inhibitor, clade A (alpha 1 antiproteinase, antitrypsin), member 3, isoform CRA_c
  A0A024RD41   3012                          731.6666667                                 -2.04146333   RAB23, member RAS oncogene family, isoform CRA_a
  A0A024R1Z6   242.5                         59                                          -2.03919789   Vesicle amine transport protein 1 homolog (T. californica), isoform CRA_a
  Q59EQ1       478                           119.5                                       -2            Cadherin 11, type 2 isoform 1 preproprotein variant (fragment)

Note: based on protein abundance. A protein was defined as DAPs if there was a log2FC in less of -2.

[^1]: Academic Editor: Aijun Wang
